$1.67
+0.02
(+1.21%)▲
1.8%
Downside
Day's Volatility :2.96%
Upside
1.18%
71.84%
Downside
52 Weeks Volatility :86.94%
Upside
53.61%
Period | Durect Corp | Russel 2000 | Index (Russel 2000) |
---|---|---|---|
3 Months | 77.17% | 0.0% | 0.0% |
6 Months | 111.54% | 0.0% | 0.0% |
1 Year | -47.28% | 0.0% | 0.0% |
3 Years | -88.04% | -20.2% | -20.2% |
Market Capitalization | 51.7M |
Book Value | $0.27 |
Earnings Per Share (EPS) | -0.93 |
PEG Ratio | -0.46 |
Wall Street Target Price | 6.75 |
Profit Margin | -279.77% |
Operating Margin TTM | -312.92% |
Return On Assets TTM | -41.74% |
Return On Equity TTM | -196.94% |
Revenue TTM | 8.3M |
Revenue Per Share TTM | 0.3 |
Quarterly Revenue Growth YOY | -11.1% |
Gross Profit TTM | 16.5M |
EBITDA | -31.5M |
Diluted Eps TTM | -0.93 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.85 |
EPS Estimate Next Year | -1.06 |
EPS Estimate Current Quarter | -0.22 |
EPS Estimate Next Quarter | -0.18 |
What analysts predicted
Upside of 304.19%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 18.6M | ↓ 62.25% |
Net Income | -25.3M | ↑ 585.3% |
Net Profit Margin | -136.4% | ↓ 128.89% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 29.6M | ↑ 59.25% |
Net Income | -22.8M | ↓ 10.01% |
Net Profit Margin | -77.08% | ↑ 59.32% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 30.1M | ↑ 1.85% |
Net Income | -2.5M | ↓ 88.93% |
Net Profit Margin | -8.38% | ↑ 68.7% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 14.0M | ↓ 53.58% |
Net Income | -38.1M | ↑ 1411.7% |
Net Profit Margin | -272.77% | ↓ 264.39% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 19.3M | ↑ 37.96% |
Net Income | -35.6M | ↓ 6.66% |
Net Profit Margin | -184.54% | ↑ 88.23% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 8.5M | ↓ 55.67% |
Net Income | -27.6M | ↓ 22.37% |
Net Profit Margin | -323.16% | ↓ 138.62% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 3.3M | ↓ 72.32% |
Net Income | -9.4M | ↑ 235.94% |
Net Profit Margin | -284.77% | ↓ 261.31% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.1M | ↓ 38.04% |
Net Income | -12.2M | ↑ 29.51% |
Net Profit Margin | -595.23% | ↓ 310.46% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.1M | ↑ 1.31% |
Net Income | -11.2M | ↓ 8.55% |
Net Profit Margin | -537.29% | ↑ 57.94% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.7M | ↓ 16.19% |
Net Income | -3.0M | ↓ 73.03% |
Net Profit Margin | -172.88% | ↑ 364.41% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 2.7M | ↑ 53.04% |
Net Income | -1.4M | ↓ 52.21% |
Net Profit Margin | -53.99% | ↑ 118.89% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.8M | ↓ 31.55% |
Net Income | -7.6M | ↑ 430.4% |
Net Profit Margin | -418.34% | ↓ 364.35% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 50.0M | ↓ 5.86% |
Total Liabilities | 30.0M | ↓ 5.14% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 86.0M | ↑ 72.04% |
Total Liabilities | 63.2M | ↑ 110.54% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 75.6M | ↓ 12.07% |
Total Liabilities | 35.5M | ↓ 43.75% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 92.0M | ↑ 21.61% |
Total Liabilities | 34.2M | ↓ 3.71% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 60.1M | ↓ 34.67% |
Total Liabilities | 35.1M | ↑ 2.65% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 45.2M | ↓ 24.81% |
Total Liabilities | 30.4M | ↓ 13.41% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 60.1M | ↓ 12.23% |
Total Liabilities | 35.1M | ↑ 4.45% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 58.3M | ↓ 2.91% |
Total Liabilities | 43.0M | ↑ 22.47% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 48.7M | ↓ 16.61% |
Total Liabilities | 43.2M | ↑ 0.35% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 54.7M | ↑ 12.48% |
Total Liabilities | 40.3M | ↓ 6.57% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 45.2M | ↓ 17.43% |
Total Liabilities | 30.4M | ↓ 24.59% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 36.2M | ↓ 19.85% |
Total Liabilities | 27.9M | ↓ 8.17% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -19.8M | ↑ 1370.59% |
Investing Cash Flow | 4.5M | ↓ 64.25% |
Financing Cash Flow | 17.5M | ↑ 38.48% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 11.1M | ↓ 156.21% |
Investing Cash Flow | -27.3M | ↓ 702.25% |
Financing Cash Flow | 19.5M | ↑ 11.56% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -38.7M | ↓ 448.65% |
Investing Cash Flow | 9.4M | ↓ 134.52% |
Financing Cash Flow | 15.7M | ↓ 19.7% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -37.3M | ↓ 3.6% |
Investing Cash Flow | 15.3M | ↑ 62.33% |
Financing Cash Flow | 50.5M | ↑ 222.68% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -26.3M | ↓ 29.57% |
Investing Cash Flow | 19.8M | ↑ 29.55% |
Financing Cash Flow | 83.0K | ↓ 99.84% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.4M | ↑ 277.34% |
Investing Cash Flow | 1.5M | ↓ 72.98% |
Financing Cash Flow | 24.0K | ↓ 4.0% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.3M | ↑ 10.13% |
Investing Cash Flow | -4.9M | ↓ 433.6% |
Financing Cash Flow | 10.0M | ↑ 41566.67% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.3M | ↑ 0.86% |
Investing Cash Flow | 1.8M | ↓ 137.39% |
Financing Cash Flow | -34.0K | ↓ 100.34% |
Sell
Neutral
Buy
Durect Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Durect Corp | 25.48% | 111.54% | -47.28% | -88.04% | -83.08% |
![]() Neurocrine Biosciences Inc. | 7.56% | 2.78% | 45.55% | 52.55% | 67.01% |
![]() Haleon Plc Spon Ads | 7.53% | 11.87% | 3.28% | 23.35% | 23.35% |
![]() Zoetis Inc. | 5.77% | -5.62% | -5.85% | -9.99% | 57.03% |
![]() Viatris Inc. | 12.75% | -1.42% | 12.21% | -15.03% | -28.03% |
![]() Catalent, Inc. | 4.08% | 11.91% | 19.53% | -48.27% | 2.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Durect Corp | NA | NA | -0.46 | -0.85 | -1.97 | -0.42 | NA | 0.27 |
![]() Neurocrine Biosciences Inc. | 39.75 | 39.75 | 0.44 | 3.99 | 0.18 | 0.1 | NA | 23.72 |
![]() Haleon Plc Spon Ads | 29.9 | 29.9 | 1.69 | 0.39 | 0.07 | 0.04 | 0.02 | 1.8 |
![]() Zoetis Inc. | 34.62 | 34.62 | 2.58 | 5.77 | 0.5 | 0.14 | 0.01 | 11.07 |
![]() Viatris Inc. | 224.4 | NA | 0.06 | 2.73 | 0.0 | 0.03 | 0.04 | 16.81 |
![]() Catalent, Inc. | 211.02 | NA | 2.06 | 0.2 | -0.28 | -0.01 | NA | 19.96 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Durect Corp | Buy | $51.7M | -83.08% | NA | -279.77% |
![]() Neurocrine Biosciences Inc. | Buy | $14.7B | 67.01% | 39.75 | 18.65% |
![]() Haleon Plc Spon Ads | Buy | $41.0B | 23.35% | 29.9 | 9.64% |
![]() Zoetis Inc. | Buy | $82.0B | 57.03% | 34.62 | 27.38% |
![]() Viatris Inc. | Hold | $14.2B | -28.03% | 224.4 | -0.37% |
![]() Catalent, Inc. | Hold | $10.6B | 2.08% | 211.02 | -28.44% |
Insights on Durect Corp
Revenue is down for the last 2 quarters, 2.66M → 1.82M (in $), with an average decrease of 31.6% per quarter
Netprofit is down for the last 2 quarters, -1.44M → -7.64M (in $), with an average decrease of 430.4% per quarter
In the last 1 year, Neurocrine Biosciences Inc. has given 45.5% return, outperforming this stock by 92.8%
In the last 3 years, Neurocrine Biosciences Inc. has given 52.6% return, outperforming this stock by 140.6%
Ingalls & Snyder LLC
Vanguard Group Inc
Richmond Brothers Inc
Gagnon Securities LLC
BlackRock Inc
Geode Capital Management, LLC
durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use
Organization | Durect Corp |
Employees | 48 |
CEO | Dr. James E. Brown D.V.M. |
Industry | Health Technology |
A Spac I Acquisition Corp
$1.67
+1.21%
Keyarch Acquisition Corp
$1.67
+1.21%
Connexa Sports Technologies Inc
$1.67
+1.21%
Us Value Etf
$1.67
+1.21%
First Wave Biopharma Inc
$1.67
+1.21%
Global X Msci Next Emerging
$1.67
+1.21%
Fat Projects Acquisition Corp
$1.67
+1.21%
Capital Link Global Fintech
$1.67
+1.21%
Applied Uv Inc
$1.67
+1.21%